Background
==========

Left ventricular hypertrabeculation/noncompaction (LVHT) is a cardiac abnormality of unknown etiology which has been described in children as well as in adults. LVHT has been reported in association with various cardiac abnormalities, like Ebstein anomaly, pulmonary stenosis or atrial septal defect \[[@B1]-[@B12]\]. LVHT is associated with several extracardiac, especially neurological, abnormalities. LVHT has been reported in association with epilepsy, facial dysmorphism or minor anomalies \[[@B1],[@B4],[@B12]-[@B18]\]. Several chromosomal aberrations have been identified in LVHT associated with heart defects \[[@B1],[@B4],[@B8],[@B10],[@B12],[@B15]-[@B17]\]. We present a pediatric patient with LVHT and other right and left heart defects, epilepsy and minor facial anomalies in whom microarray-based comparative genomic hybridization (array CGH) detected new copy number variants (CNVs).

Case presentation
=================

A 5.5-year old girl had undergone surgical patch closure of a large secundum atrial septal defect with valvotomy of a moderate pulmonary stenosis at the age of 2 months; a mild aortic stenosis with a thickened tricuspid aortic valve was not corrected. She was born as the first child to non-consanguineous parents. The family history was negative for sudden cardiac death, but the maternal grandfather had epileptic seizures without fever in his youth. At the age of 12 months the girl suffered from a first afebrile seizure and at the age of 23 months from a first febrile seizure. Four months later she suffered from a series of afebrile seizures. Therefore valproic acid was started and maintained for 2 years. During this treatment she was seizure-free with normal electroencephalogram (EEG). After tapering valproic acid over a period of 2 months, short generalized paroxysmal discharges appeared on the EEG for the first time without clinical correlate. One year later she suffered from two further uncomplicated febrile seizures. Since then she is seizure-free without anticonvulsive treatment but the 24 h-EEG persistently shows subclinical absences. Since the intellectual and physical development of the patient is normal it was decided together with the parents not to restart the antiepileptic medication but to follow her up closely. Cerebral magnetic resonance imaging was normal. Clinical cardiologic, echocardiographic and neurologic examinations of the first degree relatives were normal except for the mother who showed epicanthic folds and hypertelorism. Unfortunately, the maternal grandfather did not consent with any investigations.

At inspection, she had bilateral epicanthic folds; broad eyebrows, a broad nasal tip and hypertelorism, however no ptosis or low-set ears (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Her body weight was 18 kg (25^th^ percentile), head circumference 51 cm (50^th^ percentile) and height 115 cm (75^th^ percentile). She did not complain about any cardiac symptoms and did not suffer from heart failure. Twelve-lead electrocardiogram showed normal sinus rhythm alternating with an atrio-ventricular-nodal rhythm and an incomplete right-bundle-branch-block. Twenty-four-hour electrocardiogram showed sporadic ventricular and supraventricular ectopic beats. Echocardiography revealed a mild residual valvular pulmonary stenosis with moderate pulmonary valve regurgitation and mild aortic valve stenosis with mild aortic regurgitation. Left ventricular function was normal, however, extensive hypertrabeculation resulting in a two-layered structure of the myocardium was visible in the mid-ventricular and apical segments of the left ventricle, consistent with the diagnosis of LVHT (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Review of previous echocardiographic examinations disclosed that LVHT had been present already at age 2 years. As a primary prophylaxis for cardiac embolism aspirin 50 mg/d was started. Since she was symptom-free, no further cardiac medication was prescribed. At the latest follow-up investigation in September 2011, she was in a good cardiac and neurologic condition, no seizures had recurred and her intellectual development was normal. Echocardiography was unchanged.

![Frontal pictures of the patient showing bilateral epicanthic folds, broad eyebrows, broad nasal tip and hypertelorism.](1471-2350-13-60-1){#F1}

![Lateral pictures of the patient showing bilateral epicanthic folds, broad eyebrows, broad nasal tip and hypertelorism.](1471-2350-13-60-2){#F2}

![Echocardiographic apical 4-chamber-view showing the hypertrabeculated left ventricular apex with a two-layered structure.](1471-2350-13-60-3){#F3}

![Using colour-Doppler-sonography the intertrabecular recesses are perfused from the ventricular cavity.](1471-2350-13-60-4){#F4}

Molecular genetic analyses of the *PTPN11, KRAS, RAF1 and SOS1* genes were negative. Array CGH using a 1 M oligonucleotide microarray platform (Agilent Technologies, Santa Clara, CA) was performed to screen genome-wide for submicroscopic deletions and duplications \[[@B19]\]. Genomic positions are given according to genome-build hg18. Array CGH detected five previously not described CNVs as listed in Table [1](#T1){ref-type="table"}. FISH analyses were not carried out because of the size of the CNVs. Regarding the duplications it could not be assessed whether they were tandem-duplications on the same locus or whether the duplicated fragment was inserted or translocated in another chromosome. By application of quantitative Real-Time PCR (qPCR) we could show, however, that none of the changes had developed de novo. All five CNVs are currently not listed in the Toronto Database of Genomic Variants (DGV), therefore, have to be considered as non-frequent variants in normal controls. Follow-up and testing of the index patient and her parents by qPCR revealed that all CNVs were inherited from one of the unaffected parents (maternal: deletion 1q42.3, duplication 3q26.32q26.33; paternal: duplication 14q32.11, deletion and duplication 20q13.33). We thus conclude that these changes are most likely not clinically significant CNVs but rare benign variants, although a reduced penetrance of inherited CNVs cannot be excluded.

###### 

Array CGH detected CNVs

  **Chromosomal band**   **CNV**   **Start**   **End**     **Genes**                                           
  ---------------------- --------- ----------- ----------- -------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1p12                   del       120338195   120404356   *NOTCH2* (intragenic, exon 2--4)                   homolog of Drosophila Notch2, MIM 600275
  1q42.3                 del       234409418   234422919   *GPR137B* (intragenic, exon 5)                     G protein-coupled receptor 137B, MIM 604658
  3q26.32q26.33          dup       180445165   180668097   *KCNMB3* (5\' partial), *ZNF639*, *MFN1*, *GNB4*   potassium large conductance calcium-activated channel, subfamily M beta member 3, MIM 605222; zinc finger protein 639; Mitofusin 1, MIM 608506; Guanine nucleotide-binding protein beta-4, MIM 610863
  14q32.11               dup       89942827    90019073    *CALM1* (3\' partial)                              Calmodulin 1, MIM 114180
  20q13.33               del       59412001    59460188    *CDH4* (intronic)                                  cadherin 4 (retinal cadherin), MIM 603006
  20q13.33               dup       59597204    59629701    *CDH4* (intronic)                                   

Positions according to hg18.

Discussion
==========

LVHT associated with atrial septal defect with or without pulmonary valve stenosis has been reported by several authors \[[@B2]-[@B9],[@B11]\]. In most of these patients atrial septal defect and LVHT were associated with several other cardiac and extracardiac anomalies, and genetic studies revealed various mutations as listed in Table [2](#T2){ref-type="table"}. However, the combination of a secundum type atrial septal defect with pulmonary stenosis and aortic stenosis in combination with LVHT has not been described to date. LVHT associated with seizures has been reported in children with monosomy 1p36 \[[@B1],[@B15],[@B16]\] and interstitial 1q43 deletion \[[@B4]\]. Facial anomalies and LVHT have been described previously in children with developmental impairment, interstitial 1q43 deletion \[[@B4]\], deletion 1p36 syndrome \[[@B1]\], interstitial 8p23.1 deletion \[[@B12]\], point mutations and deletions of the *NSD1* gene located at chromosome 5q35 \[[@B17]\] and in an adult with sex chromosome mosaicism, male phenotype and the karyotype mos45,X(28)/46,X,+mar(21)/47,X, + 2 mar(1) \[[@B18]\].

###### 

Reports about left ventricular noncompaction/hypertrabeculation with atrial septal defect

  **Ref.**     **Age/sex**   **Additional cardiac findings**                                       **Extracardiac comorbidity**                                               **Follow-up**                                       **Genetic findings**
  ------------ ------------- --------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------- ----------------------------
  \[[@B2]\]    39y/f         Eb, heart failure, EF \<55                                            NI                                                                         NI                                                  *MYH7* mutation
  \[[@B9]\]    16y/m         Right pulmonary vein aplasia, left-sided pulmonary vein obstruction   Right lung hypoplasia                                                      Balloon dilatation, interventional ASD closure      NI
  \[[@B10]\]   NI/m          AV-block I, syncope                                                   NI                                                                         NI                                                  *NKX2.5* mutation
  \[[@B11]\]   23y/m         VSD                                                                   NI                                                                         NI                                                  NI
  \[[@B3]\]    Birth/f       VSD                                                                   Agenesis of corpus callosum, facial dysmorphism, febrile seizures          Alive at 3 years, delayed psychomotor development   Interstitial 1q43 deletion
  \[[@B5]\]    16y/m         None                                                                  NI                                                                         NI                                                  E101K *ACTC* mutation
  \[[@B5]\]    62y/m         None                                                                  NI                                                                         NI                                                  E101K *ACTC* mutation
  \[[@B6]\]    1 m/m         None                                                                  Hypotonia, developmental delay, nystagmus, strabismus, failure to thrive   NI                                                  *MMACHC* mutation
  \[[@B7]\]    5d/m          EF \<55, PDA, Eb                                                      NI                                                                         Alive                                               NI
  \[[@B7]\]    1d/f          None                                                                  Ni                                                                         Alive                                               NI
  \[[@B7]\]    6 m/m         Ectopic atrial rhythm, VSD                                            NI                                                                         Alive                                               NI
  \[[@B7]\]    5y/f          WPW, Eb                                                               NI                                                                         Alive                                               NI
  \[[@B7]\]    6 m/f         EF \<55, VSD, SAS, Coa                                                NI                                                                         Dead                                                NI
  \[[@B7]\]    2 m/m         VSD                                                                   NI                                                                         Alive                                               NI
  \[[@B7]\]    1 m/f         SVT, VT, VSD, PDA, DILV                                               NI                                                                         Alive                                               NI
  \[[@B7]\]    Birth/f       EF \<55, PDA                                                          NI                                                                         Dead                                                NI
  \[[@B7]\]    1d/f          VSD, PDA, BAV, LSVC                                                   NI                                                                         Alive                                               NI
  \[[@B7]\]    9 m/f         EF \<55, VSD                                                          NI                                                                         Dead                                                NI
  \[[@B7]\]    2d/m          EF \<55, VSD                                                          NI                                                                         Dead                                                NI
  \[[@B7]\]    3 m/m         VSD                                                                   NI                                                                         Alive                                               NI
  \[[@B7]\]    6d/m          EF \<55                                                               NI                                                                         Alive                                               NI
  \[[@B7]\]    9 m/m         VSD                                                                   NI                                                                         Alive                                               NI
  \[[@B7]\]    7d/f          EF \<55                                                               NI                                                                         Alive                                               NI
  \[[@B7]\]    1 m/m         EF \<55                                                               NI                                                                         Alive                                               NI
  \[[@B8]\]    Birth/f       Sinusbradycardia, pulmonary valve atresia                             BLI, ACV, abdominal situs ambiguous, polysplenia                           Dead                                                Linkage to 6p24.3-21.2
  \[[@B8]\]    22y/m         Sinusbradycardia, AF                                                  BLI, ACV                                                                   Alive                                               Linkage to 6p24.3-21.2
  \[[@B8]\]    32y/f         Pulmonary valve stenosis, sick sinus syndrome                         ACV, polysplenia, malrotation of the gut                                   Alive                                               Linkage to 6p24.3-21.2
  \[[@B8]\]    59y/m         AF, heart failure, EF \<55                                            Polysplenia                                                                Died suddenly                                       Linkage to 6p24.3-21.2

NI, not indicated; EF, \<55 left ventricular ejection fraction \<55 %; PDA, patent ductus arteriosus; Eb, Ebstein anomaly of the tricuspid valve; VSD, ventricular septal defect; WPW, Wolff-Parkinson-White; SAS, subaortic stenosis; Coa, coarctation of the aorta; SVT, supraventricular tachycardia; VT, ventricular tachycardia; DILV, double-inlet left ventricle; BAV, bicuspid aortic valve; LSVC, left-sided superior vena cava; ACV, azygous continuation of the vena cava inferior; AF, atrial fibrillation; BLI, bronchial left isomerism.

CNVs are structural genomic variants due to deletions or duplications, resulting in a copy-number change of the respective genomic region. CNVs may include entire genes, regions of transcribed sequence, or nontranscribed sequences. Whereas the duplication or deletion of a gene can be expected to have an effect on gene dosage, the consequences of CNVs in nontranscribed sequences are less clear \[[@B20]\]. According to the resolution of the applied array platform (5--10 kb genome-wide) we currently do not have evidence for a clinically relevant chromosomal imbalance i.e. gain or loss of genomic material. However, it is still possible that an underlying chromosomal abnormality either below the detection limit of the array or a balanced rearrangement which is undetectable by array CGH is causative for the described phenotype. This assumption is supported by the previously reported chromosomal defects in LVHT associated with facial anomalies, atrial septal defect and epilepsy. The presence of a chromosomal abnormality as the underlying defect is further substantiated by the fact that LVHT is particularly prevalent in young patients with chromosomal abnormalities \[[@B21]\].

In patients with epilepsy, an association with a truncation mutation of the *KCNMB3* gene has been described which is partly affected from the duplication on chromosome 3 \[[@B22]\]. However, consequences of the duplication on the transcripts of this gene were not tested, and this is why such a presumed association remains speculative.

The first CNV detected in our patient (1p12 deletion) results in a deletion of part of the *NOTCH2* gene that can be mutated in Alagille syndrome, a multisystem disorder with predominantly liver-, skeletal, ophthalomologic and renal abnormalities \[[@B23]\]. We consider Alagille syndrome unlikely in our patient since she did not show any of these abnormalities, although highly variable expressivity of the affected systems has been described in subjects with NOTCH2 mutations \[[@B24]\].

Conclusions
===========

This case shows that childhood LVHT may be associated with other cardiac abnormalities, central nervous system disease and minor facial anomalies. Despite this complex phenotype de novo microdeletions or microduplications were not detected by array CGH. Further investigations, such as whole exome sequencing, could reveal point mutations and small indels as the possible cause.

Consent
-------

The father of the patient has given his consent for the case report to be published.

Methods
=======

Microarray-based comparative genomic hybridization (Array CGH)
--------------------------------------------------------------

Array CGH was performed using the 1 M oligonucleotide array (SurePrint G3 Human CGH 1x 1 M microarray, Agilent Technologies, Santa Clara, CA). We used female reference DNA (Human Genomic DNA female, Promega). Processing of the array was done according to the manufacturer\'s instructions. Extraction of microarray TIFF images had been done by "Feature Extraction" and the following data analysis was done by the "DNA Analytics 4.0" software (both Agilent Technologies, Santa Clara, CA). The following analysis settings in DNA analytics software were applied: algorithm ADM-2, filter 5 probes, log2ratio 0.29.

Quantitative real-time PCR (qPCR)
---------------------------------

Genomic DNA samples of the index patient and her parents were obtained from EDTA-blood. Amplicons were located within the aberrant regions as detected by array CGH and in flanking regions. Primer sequences can be obtained upon request. qPCR was performed as previously described \[[@B20]\].
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